|
WO2017066552A1
|
|
Methods and compositions for the treatment of epidermolysis bullosa
|
|
WO2016010844A1
|
|
Methods and compositions for the treatment of stroke
|
|
US2015238560A1
|
|
Methods and compositions for the delayed treatment of stroke
|
|
WO2015057403A2
|
|
Compositions and methods for treatment of inflammatory bowel disease
|
|
US2015105335A1
|
|
Peptide compositions
|
|
WO2015054005A1
|
|
Compositions and methods for treatment of bdnf-related conditions
|
|
AU2014332346A1
|
|
Novel peptide compositions
|
|
EP3003345A1
|
|
Angiotensin peptides in treating marfan syndrome and related disorders
|
|
MX2015003407A
|
|
Oral formulations of angiotensin.
|
|
WO2013158959A1
|
|
Compositions and methods for treatment of graft-versus-host disease
|
|
AU2013216910A1
|
|
Compositions and methods for treatment of peripheral vascular disease
|
|
US8557958B1
|
|
Compositions and methods for treatment of diabetes
|
|
US8633158B1
|
|
Angiotensin in treating brain conditions
|
|
CN104302305A
|
|
Angiotensins for treatment of fibrosis
|
